Verrica Pharmaceuticals Inc.

VRCA

US92511W1080

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 16:25:35 17/07/2024 BST			5-day change	1st Jan Change
8.52 ^USD	-3.29%		+13.04%	+18.44%

07-01	Verrica Pharmaceuticals Settles Cantharidin-Related Lawsuit With Dormer Labs	MT
06-28	Verrica Pharmaceuticals Inc. Enters into an Amendment to Its Credit Agreement	CI

Verrica Appoints Neil D. Dehenes as Vice President of Distribution, Trade and Channel Strategy

January 07, 2019 at 12:00 pm

Verrica Pharmaceuticals Inc. announced the appointment of Neil D. DeHenes as Vice President of Distribution, Trade and Channel Strategy.

Latest news about Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Settles Cantharidin-Related Lawsuit With Dormer Labs	07-01	MT
Verrica Pharmaceuticals Inc. Enters into an Amendment to Its Credit Agreement	06-28	CI
Verrica Pharmaceuticals Amends Licensing Agreement With Torii Pharmaceutical for Phase 3 Trial of Ycanth	05-15	MT
Verrica Pharmaceuticals Inc. Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study Ycanth for the Treatment of Common Warts	05-15	CI
HC Wainwright Adjusts Price Target on Verrica Pharmaceuticals to $14 From $13, Maintains Buy Rating	05-14	MT
Needham Adjusts Price Target on Verrica Pharmaceuticals to $16 From $8, Keeps Buy Rating	05-14	MT
Transcript : Verrica Pharmaceuticals Inc., Q1 2024 Earnings Call, May 13, 2024	05-13
Verrica Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Earnings Flash (VRCA) VERRICA PHARMACEUTICALS Reports Q1 Revenue $3.8M, vs. Street Est of $2.7M	05-13	MT
Verrica Pharmaceuticals' Ycanth Gets New Chemical Entity Status, Orange Book Listing	03-26	MT
Verrica Pharmaceuticals Announces that YCANTH? Receives New Chemical Entity Status and Orange Book Listing from the FDA	03-26	CI
HC Wainwright Adjusts Verrica Pharmaceuticals Price Target to $13 From $12, Maintains Buy Rating	03-01	MT
Transcript : Verrica Pharmaceuticals Inc., Q4 2023 Earnings Call, Feb 29, 2024	02-29
Verrica Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Verrica Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-29	CI
Earnings Flash (VRCA) VERRICA PHARMACEUTICALS Reports Q4 Revenue $2M, vs. Street Est of $950,000	02-29	MT
Verrica Pharmaceuticals Sues Dormer Labs for Promoting Unapproved Cantharidin Drugs in US	02-05	MT
Verrica Pharmaceuticals Receives Permanent J-Code for YCANTH from Centers for Medicare and Medicaid Services	01-29	CI
Ligand Pharma's at-home skin treatment gets FDA approval	01-05	RE
Verrica Pharmaceuticals Inc. Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315	01-05	CI
Lytix Biopharma’s License Partner Finalizes Patient Dosing in Phase 2 Trial of Skin Cancer Therapy	01-05	MT
Verrica Pharmaceuticals Doses Last Patient in Part 2 of Phase 2 Study of Potential Skin Cancer Treatment	01-05	MT
Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH?? for the Treatment of Common Warts	01-04	CI
Verrica Pharmaceuticals Partners With Walgreens to Distribute YCANTH Therapy	01-03	MT
Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH?	01-03	CI

Chart Verrica Pharmaceuticals Inc.

Duration

Period

More charts

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts.

Sector

Pharmaceuticals

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Verrica Pharmaceuticals Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.81 USD

Average target price

15.5 USD

Spread / Average Target

+75.94%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
VERRICA PHARMACEUTICALS INC.	+18.44%	374M
ELI LILLY AND COMPANY	+57.05%	848B
NOVO NORDISK A/S	+31.64%	627B
JOHNSON & JOHNSON	-0.85%	363B
MERCK & CO., INC.	+14.97%	318B
ABBVIE INC.	+12.53%	299B
ASTRAZENECA PLC	+15.25%	243B
NOVARTIS AG	+16.73%	225B
AMGEN INC.	+15.51%	179B
PFIZER, INC.	+3.62%	167B

Other Pharmaceuticals

Verrica Pharmaceuticals Inc.

Equities

VRCA

US92511W1080

Pharmaceuticals

Verrica Appoints Neil D. Dehenes as Vice President of Distribution, Trade and Channel Strategy

Latest news about Verrica Pharmaceuticals Inc.

Chart Verrica Pharmaceuticals Inc.

Company Profile

Income Statement Evolution

Ratings for Verrica Pharmaceuticals Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals